BigHat Biosciences

We welcome Anisha Keshavan, Crystal H. and Vanessa Le! Anisha joins us as a Senior Data Scientist II. Anisha will be focusing on supercharging data analysis and visualization in our proprietary LIMS, Reccy. Anisha earned her BS in Aerospace Engineering and Applied Math at UCLA and her PhD in Bioengineering at University of California, San Francisco + University of California, Berkeley. She previously served as Lead Data Scientist at Octave and has extensive experience in data visualization, data-focused app development, and computer vision. Crystal joins as Principal Data Scientist. Crystal will develop a data science strategy focused on evaluating and refining the ML-driven antibody design methods deployed on our platform, and aligning the scaling of data generation and processing with improved model performance and therapeutic program advancement. Crystal is a PhD researcher with over a decade of experience spanning human genomics, experimental design, optimization, and statistical modeling. She has led projects at Amazon, Zymergen, and Google [X, the moonshot factory]. Vanessa Le joins BigHat as an Associate Software Engineer II. Vanessa will be working on tools to accelerate how we design and track antibodies through Reccy as well as improve ways in which we capture experimental data. Vanessa is a recent graduate from Northeastern University with a degree in Computer Science. She completed a software engineering co-op at BigHat before coming back to work with the team as a full-time employee. She is passionate about computer science due to its problem-solving nature and loves being able to see the positive impact that her work brings to people's lives. Welcome to the BigHat team, Anisha, Crystal and Vanessa! https://lnkd.in/grt3Vjx9  

Peyton Greenside, our Co-founder and CSO, is training with the BigHat team as she prepares for the Timmerman Traverse for Sickle Forward this September. She’ll be climbing Mt. Kilimanjaro to help raise awareness and funds for sickle cell disease treatment in sub-Saharan Africa. We’re proud to support her in this important mission. Only 4 days left to support! https://lnkd.in/g6PyYPJt #TimmermanTraverse #SickleForward #BigHat #SCD #MtKilimanjaro

We’re excited to share that BigHat Biosciences was featured in Genetic Engineering & Biotechnology News. Our co-founder and CSO, Peyton Greenside, discussed how AI is advancing traditional antibody engineering by leveraging diverse antibody sequences, modeling multiple properties simultaneously, and generating novel antibodies to meet unmet medical needs. To read full article: https://lnkd.in/dRUcbggP 

🚀 Exciting News! 🚀 We are thrilled to announce that BigHat Biosciences has been featured on 2024’s Fierce Biotech 15! This prestigious recognition highlights our fierce approach in leveraging machine learning and synthetic biology for high quality antibody drug discovery. A huge shoutout to our dedicated team and partners who make this possible! Together, we're pushing the boundaries of biotech and making strides towards better treatments for patients worldwide. 🌍 Check out the full article to learn more about our journey and vision: https://lnkd.in/gUgbkwhw

We welcome Mira, Ian and Sichen to BigHat! Mira Markova joins us as Scientist II, Platform. Mira will lead internal cell-line development and engineering efforts at BigHat, supporting our Programs and Discovery needs. Mira received her B.S. in France, and M.S. split between France and the US. She then did her PhD at the University of Illinois Chicago, and two postdocs at University of California, Davis and The University of Texas at Arlington. Before joining BigHat, Mira had industry stints at Aragen Life Sciences, Aridis Pharmaceuticals, and Inscripta, Inc. , focusing on cell line development and gene editing technologies. Ian Eigl joins us as an Associate Scientist, Display Technologies where he will help in expanding BigHat’s display technology capabilities. Ian received a B.S. in Chemical and Biomolecular Engineering at University of California, Berkeley, and then worked in Jim Wells' group at the University of California, San Francisco where he gained extensive experience with phage display. He then transitioned to the antibody discovery and engineering team at Tizona Therapeutics, Inc.  Sichen Liang joins us as a Research Associate II, Protein Sciences and will help expand the capabilities of our developability workflows across our platform. Sichen received a B.S. in Chemical Engineering from Virginia Tech and an M.S. in Chemical Engineering from the University of California, Berkeley before joining Sanofi in South San Francisco. At Sanofi, she gained extensive experience with protein expression, purification, and characterization across multiple platforms during pre-clinical assessments of TCEs. Welcome to the team Mira, Ian and Sichen! https://lnkd.in/grt3Vjx9

BigHat’s Chief Business Officer, Elizabeth Schwarzbach, joined Judy Khan Shaw on NYSE Floor Talk to discuss BigHat’s mission and cutting-edge approach to drug discovery, which combines AI and ML with a rapid and high-quality laboratory to develop next-gen antibodies on our Milliner™ platform. Watch the full recording: https://lnkd.in/gG2CqdB3   

Please donate and support Peyton Greenside, BigHat's co-founder, as she hikes Kilimanjaro to help those suffering from Sickle Cell Disease.

🏔️Join us in supporting Peyton Greenside from the BigHat team as she takes on the Timmerman Traverse for Sickle Forward! 🌍✨ This September, Peyton will hike to the summit of Mt. Kilimanjaro (19,340 ft / 5,895 m) to raise funds for Sickle Cell Disease (SCD) diagnosis and treatment in sub-Saharan Africa. 💪🏔️ SCD affects millions, with the highest prevalence in sub-Saharan Africa. Many children go undiagnosed and lack access to basic treatment, leading to high mortality rates. We invite you to support Peyton and the entire Timmerman Traverse team in their cause to help fund systematic newborn screening and treatment programs in sub-Saharan Africa, saving countless lives and giving children the chance for a healthier future. To address the unmet need of patients with SCD, BigHat has designed a next-generation antibody now in preclinical development to treat and prevent SCD vaso-occlusive crises. Stay tuned for more information about our program! 📅 Expedition Dates: Sept. 11-17, 2024 🎯 Fundraising Goal: $50,000 🔗 Contributing to a collective $1 million effort Every dollar raised will be matched, doubling our impact! 💖 Your support can help save lives! Let's climb higher together! 🙌 https://lnkd.in/g6PyYPJt #TimmermanTraverse #SickleForward #BigHat #SCD #MtKilimanjaro

We welcome Tiffany Barth, Eman K. and Megan M.! Tiffany joins us as a Senior Software Engineer I on the Lab Systems engineering team. She will be focusing on projects aimed at deepening our integration with the lab and our proprietary LIMS, Reccy. Tiffany is a full-stack software engineer with over 14 years of experience working in biotech. Previously, she was a software engineer at Invitae working on building and maintaining tools for translating scientific literature into organized medical content. She graduated from Carnegie Mellon University with a double major in chemical engineering and biomedical engineering. Eman and Meg join us as Research Associates II to the Production team. They will help scale our production capabilities to meet the demand from our growing pipeline of programs. Eman earned her bachelor's degree in Natural Sciences from Minerva University in 2020. After three years of working at Color's high-throughput COVID-19 lab, she returned to academia and is now one year into pursuing a master's degree in biotechnology at the University of San Francisco Meg is a research associate with experience in lab operations and LC-MS based biomarker discovery. She graduated with a B.S. in Biology from Arizona State University in 2021 and subsequently transitioned to the Bay Area to pursue a career in biotech. Prior to joining BigHat, Meg served as a member of the proteomics R&D team at PrognomiQ Inc, where she actively participated in multiple cohort studies and platform development initiatives aimed at creating diagnostic assays for early detection of cancers and other complex diseases. Welcome to the BigHat team, Tiffany, Eman and Meg! https://lnkd.in/grt3Vjx9

We welcome Monique Merchant, Somnath Nirakari, and Josh Dillen! Monique joins us as a Scientist I as part of the Platform Biology team at BigHat. Monique will lead high-throughput Discovery cell-based productionization, spearheading cell line onboarding, cell-based assay validation, and characterization workflows for all discovery efforts. Monique is a biochemist with a hyper-fixation on neglected tropical diseases and the impacts of climate change on global health. Prior to joining BigHat, Monique worked between the United Kingdom and Brazil developing tools to combat Oropouche fever, creating preliminary diagnostic tests, vaccine candidates, and antibody therapies for Oropouche virus infections. Monique maintains expertise in the molecular biology of viral spike proteins and virus evolution with a Ph.D. in Medicine from the University of Cambridge, a M.S. from Yale University, and B.S. from Russell Sage College. Somnath joins us as Principal Engineer, Data Ops as part of our engineering team. He will work on improvements to our data infrastructure and dashboards. Somnath is an experienced software engineer with about 15 years of experience. His area of expertise is backend engineering, but having worked at multiple startups and wearing multiple hats, he has developed considerable skills in other software disciplines such as frontend development, DevOps, and platform engineering. When not working on features of a product, he is always looking at ways to make the product more reliable, faster, and fault-tolerant. He has a master's degree in computer science from the University of Florida. Before joining BigHat, Somnath worked in multiple startups in different domains such as healthcare, fintech, and consumer products. Josh joins us as an Associate Scientist in Biomolecular Characterization. He will assist in expanding our label-free biosensing capabilities, onboard characterization assays for our early-stage programs, and characterizing our late-stage lead candidates. Josh brings broad experience in protein science and expertise in biophysical characterization of large molecules. Prior to joining BigHat, Josh has contributed to a diverse range of drug development and discovery programs at Denali Therapeutics and Vir Biotechnology, Inc.. He earned his B.S. from the University of California, Santa Cruz and performed research in the DuBois lab to understand the neutralization of RSV by human antibodies. Welcome to the BigHat team, Monique, Somnath, and Josh! www.bighatbio.com/about